SCHEMBL5000568

SCHEMBL5000568

COC(=O)COc1ccc(Cl)cc1Cc1cccc(C(F)(F)F)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGDR2 Q9Y5Y4 2/20 0.47
LMNA P02545 2/20 0.47
PTGER1 P34995 2/20 0.47
PPARG P37231 2/20 0.46
PPARD Q03181 2/20 0.46
PPARA Q07869 2/20 0.46
HPGD P15428 1/20 0.46
MRGPRX4 Q96LA9 3/20 0.45
PTGDR Q13258 1/20 0.44
TP53 P04637 1/20 0.44
MAPT P10636 1/20 0.44
SCD O00767 2/20 0.43
MEN1 O00255 1/20 0.43
PLA2G1B P04054 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43
GAA P10253 1/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2C19 P33261 1/20 0.43
KMT2A Q03164 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11069880 0.84 PTGER1 (0.54) PTGDR2LMNAPTGER1HPGDPTGDR
SCHEMBL4627361 0.81 PTGDR (0.58) PTGDR2LMNAPTGDRMAPTCYP1A2
SCHEMBL5007353 0.79 MRGPRX4 (0.46) PTGDR2LMNAPTGER1HPGDMRGPRX4
SCHEMBL4627039 0.78 PTGDR2 (0.52) PTGDR2LMNAPPARDPTGDRMAPT
SCHEMBL4656398 0.76 PTGER1 (0.52) PTGDR2PTGER1PTGDR
SCHEMBL4626978 0.76 MAPT (0.65) PTGDR2LMNAPTGDRMAPTTDP1
SCHEMBL5007359 0.75 SCN8A (0.46) LMNAPTGER1HPGDMRGPRX4CNR1
SCHEMBL2942929 0.75 PTGDR2 (0.49) PTGDR2LMNAPTGER1HPGDPTGDR
SCHEMBL2945278 0.74 MAPT (0.70) PTGDR2LMNAPTGDRMAPTCYP1A2
SCHEMBL2944675 0.73 PTGDR (0.55) PTGDR2LMNAPTGDRMAPTCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7414063-B2 Inhibitors of Akt (protein kinase B) ELI LILLY AND COMPANY (US) 2008-08-19 US disclosed
US-20070043040-A1 Inhibitors of akt (protein kinase b) ELI LILLY AND COMPANY 2007-02-22 US disclosed
EP-1611105-A1 ISOQUINOLINE-5-SULFONIC ACID AMIDES AS INHIBITORS OF AKT (PROTEIN KINASE B) ELI LILLY AND COMPANY (US) 2006-01-04 EP disclosed
WO-2004094386-A1 ISOQUINOLINE-5-SULFONIC ACID AMIDES AS INHIBITORS OF AKT (PROTEIN KINASE B) ELI LILLY AND COMPANY (US) 2004-11-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070043040-A1 Inhibitors of akt (protein kinase b) AKT1, AKT2, BRAF PTGDR2 4128/4885LMNA 2885/4885PTGER1 3764/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.